Concepedia
Statistics
Publications
38
Citations
4.1K
H-Index
29
Active since
1984
Affiliations
Novartis (United States)(Current)
The University of Western Australia
Novartis (Switzerland)
University of California, Irvine
University College London
Ravi Anand is an author at Novartis (United States) specializing in medicine, pharmacology, and pharmacotherapy.
Publications per year
1984–2016
Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study
Ian G. McKeith, Teodoro del Ser, PierFranco Spano et al. · The Lancet · 2000 · 1.2K citations
Medicine, Neurology, Pharmacotherapy +14
A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease
Martin R. Farlow, Ravi Anand, John Messina et al. · European Neurology · 2000 · 328 citations
Medicine, Pharmacology, Pharmacotherapy +17
Two‐year, randomized, controlled study of safinamide as add‐on to levodopa in mid to late Parkinson's disease
Rupam Borgohain, József Attila Szász, Paolo Stanzione et al. · Movement Disorders · 2014 · 233 citations · Full text
Medicine, Pharmacology, Pharmacotherapy +15
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations
Anthony H.V. Schapira, Susan H. Fox, Robert A. Hauser et al. · JAMA Neurology · 2016 · 211 citations
Medicine, Neurology, Pharmacotherapy +12
Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease
Steven G. Potkin, Ravi Anand, Kirsten Fleming et al. · The International Journal of Neuropsychopharmacology · 2001 · 160 citations · Full text
Medicine, Neurology, Pharmacology +17
1–5 of 38